ChromaDex (NASDAQ:CDXC) Releases Earnings Results, Beats Estimates By $0.01 EPS

ChromaDex (NASDAQ:CDXC) posted its earnings results on Tuesday. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01, Zacks reports. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%.

ChromaDex Trading Up 1.8 %

Shares of NASDAQ CDXC traded up $0.10 during midday trading on Tuesday, reaching $5.60. The company had a trading volume of 1,094,356 shares, compared to its average volume of 379,956. The stock has a market cap of $427.74 million, a P/E ratio of 560.56 and a beta of 2.21. ChromaDex has a 1 year low of $1.57 and a 1 year high of $7.97. The business’s 50-day simple moving average is $5.62 and its 200 day simple moving average is $5.09.

Insider Activity

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on CDXC shares. Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th. Finally, HC Wainwright boosted their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.